Gujarat Terce Laboratories Limited · BSE:GUJTERC
Gujarat Terce Laboratories — Q3 FY2022 Earnings Presentation
10 slides from Gujarat Terce Laboratories's earnings presentation, Jan 24, 2022
Slide 1: Investor Presentation for Quarter ended December 31, 2021
GUJARAT TERCE LABORATORIES LIMITED January 24, 2022 To, ae Scrip Code: 524314 BSE Limited Security ID: GUJTERC Corporate Relation Department ISIN: INE499G01013 Phiroze Jeejeebhoy Towers, Dalal Streets, Mumbai- 400001, Maharashtra, India Dear Sir/Madam, Sub: Investors Presentation for Quarter ended o
Slide 2: Gujarat Terce Laboratories Limited
( GUJARAT TERCE = LABORATORIES LIMITED
Slide 3: Disclaimer
Disclaimer This presentation is for informational purposes only and does not constitute an offer or a solicitation to sell or a edition or a solicitation to submit an offer to purchase or subscribe for shares or securities of Gujarat Terce Laboratories Limited a portion thereof , constitute the basi
Slide 4: Company Overview
Company Overview Gujarat Terce has over 3 decades of experience in the Manufacturing and Marketing of branded Generics. Roots of Gujarat Terce Laboratories Limited are entrenched in the founding principles of COMPASSION and EXCELLENCE. Terce has an extensive basket of 50 Brands (125 products) with a
Slide 5: CEO's Message
CEO's Message Dear Shareholders, Gujarat Terce has delivered another quarter of positive performance. Gujarat Terce has seen strong revenue growth of 60% YoY and a PAT growth of 576 % YoY on 9 months basis. The growth is driven through a combination of, a low base, organic demand in Acute portfolio,
Slide 6: Business Highlights
Business Highlights Figures= % of total sales Figures= % of total sales 80 77 79 78 76 67 Q3FY21 33 60 Acute Segment 64 Other Brands Q3FY22 36 Precious Brands Chronic Segment 40 23 24 70 21 22 20 9MFY21 30 64 9MFY22 36 0 Q3FY21 Q3FY22 9 M FY21 9 M FY 22 0 25 50 75 Our focus on growth of precious bra
Slide 7: Business Highlights- PCPM (Per Capita Per Month)
Business Highlights- PCPM (Per Capita Per Month) Figures in lacs 2 1.92 1.87 1.75 Our Key focus area for future growth and 1.5 profitability is to Increase productivity in all geographies of operations. 1.05 We have increased PCPM over YoY. 1 The decrease in Q3 PCPM is due to expansion in newer geog
Slide 8: Financial Highlights and Corporate Highlights
Financial Highlights and Corporate Highlights 52% 2080% 738% Q3 FY 22 yoy growth Op Revenue EBIDTA PAT 9m FY 22 60% 2931% 576% yoy growth Op Revenue EBIDTA PAT AS per AIOCD data, 9MFY22, the YonY growth of IPM (Indian Pharmaceutical market) is 18.1 %. Gujarat Terce has out grown IPM and has grown by
Slide 9: Q3 FY 22- Income Statement
Q3 FY 22- INCOME STATEMENT (INR in Lacs) Q-0-Q Y-0-Y Y-O-Y Particulars Q3 FY22 Q2 FY22 Q3 vs.Q2 Q3 FY21 Q3 vs.Q3 9M FY22 9M FY21 9M vs. 9M % Change % Change % Change Revenue from Operations 1074.60 1012.63 6.12% 708.44 52% 3,080.92 1926.28 60% EBDITA 71.07 61.03 16.45% 3.26 302.07 -10.67 2931% EBDIT
Slide 10: Thank you.
Thank you. Registered office: 122/3, Ravi Estate, Bileshwarpura, Chhatral, T.A.: Kalol, Gandhinagar, Gujarat 382729 Corporate Office: D/ 801 - 802 & 1202, The First, Behind Keshavbaug party plot, Near Shivalik High-Street, Vastrapur, Ahmedabad, Gujarat 380015 Investor Contact: Contact Person: Ms. As
Gujarat Terce Laboratories — Q3 FY2022 Earnings Presentation on 6ix